trial

Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia

NCTId NCT05278156
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 189 (actual)
Sponsored by Celon Pharma SA
Primary completion 2024-06-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
189 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2021-05-19
Primary completion
2024-06-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
CPL500036 - low doseCPL500036 - high dose

Sponsors

Celon Pharma SALead Sponsor
National Center for Research and Development, PolandCollaborator

Sites

16 total
Budapest, HungaryBudapest, HungaryGyőr, HungaryKalocsa, HungarySzekszárd, HungaryBialystok, PolandBolesławiec, PolandChoroszcz, PolandGmina Świecie, PolandIvano-Frankivsk, UkraineKyiv, UkraineKyiv, Ukraine

Linked catalysts

1
Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in P — primary completion2024-06-05

Facts & assertions

4 sourced
Enrollment
189
Phase
PHASE2
Primary Completion Date
2024-06-05
Status
COMPLETED
relationships
The graph out of here
drug
CPL500036 - low dose
drug
CPL500036 - high dose
drug
lead_sponsor
Celon Pharma SA
company
collaborator
National Center for Research and Development, Poland
company
indication
Schizophrenia
indication
Schizophrenia
indication